So many scenarios in herpetic eye disease


  • Petja Vassileva Specialized Eye Hospital for Active Treatment “Acad. Pashev”
  • Yordanka Kirilova Specialized Eye Hospital for Active Treatment “Acad. Pashev”



latent herpetic infection, antiherpetic drugs, keratoplasty in corneal perforation, epidemiology of herpetic eye disease (HED)


Human herpes infections are a major cause of morbidity worldwide. Herpes
Simplex Virus (HSV) and Varicella Zoster Virus (VZV) are frequent causes of
ocular pathology. Ocular herpes is a recurrent disease, and its complications may lead to blindness. Herpetic viral infection is characterized by its ability to remain latent in the nervous system. Reactivation from the ophthalmic branch of the trigeminal ganglion may lead to recurrent attacks.
Ocular herpes is a disastrous disease causing suffering and anxiety to millions of people, and also represents important economic burden. Recently the incidence of varicella zoster virus (VZV) is increasing for unknown reasons. Published data demonstrate also that more that 50% of patients with ocular and systemic manifestation of VZV are younger than 60 years and immunocompetent. We analyze retrospectively 160 consecutive patients with ocular herpes treated at our referral specialized eye hospital, and proposed original approach to different
scenarios of disease development.


Al-Dujaili LJ, Clerkin PP, Clement C, McFerrin HE, Bhattacharjee PS et al. Ocular herpes simplex virus: how are latency, reactivation, recurrent disease and therapy interrelated? Future Microbiol. 2011; 6(8), 877-907.

Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK et al. Trends in herpes simplex virus type 1 and 2 seroprevalence in the United States, JAMA. 2006. 269(8): 964-973.

McCormick I, James C, Welton NJ, Mayaud P, Turner KME, Gottlieb SL, Foster A, Looker KJ.. Incidence of herpes simplex virus keratitis and other ocular disease: global review and estimates. Ophthalmic Epidemiol. 2022 Aug;29(4):353-362.

Roizman B, Knipe DM, Whitley RJ. Herpes Simplex Viruses. In: Knipe D. M. and Howley P. M. Eds, Fields Virology. New York, NY, Lip- pincott Williams & Wilkins. 2007; 2: 2501-2601.

Liesegang TJ. Classification of herpes simplex virus keratitis and anterior uveitis, Cornea. 1999; 18(2): 127-143.

Thygeson P. Historical observation on herpetic keratitis, Surv. Ophthalmol. 1976; 21: 82-90.

Loewenstein A. Herpes Corneæ and Virus Infection, Glasgow Med. J. 1944; 141(2): 54-62.

Sawtell NM. Comprehensive quantification of herpes simplex virus latency at the single-cell level. J. Virol. 1977; 71(7): 5423-5431.

Hengel H. Common Characteristics and Distinct Features of Human Pathogenic Herpesviruses. In: Sundmacher R. (ed.) Color Atlas of Herpetic Eye Diseases, Springer, 2009. Berlin, Heidelberg.

Faria-E-Sousa SJ, Antunes-Foschini R. Herpes simplex keratitis revisited. Arq Bras Oftalmol. 2021 Jul 14;84(5):506-512.

Valerio GS, Lin CC. Ocular manifestations of herpes simplex virus. Curr Opin Ophthalmol. 2019 Nov;30(6):525.

James C, Harfouche M, Welton NJ, Turner KME, Abu-Raddad LJ et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016. Bull. World Health Organ. 2020; 98(5): 315-329.

Kaye S, Choudhary A. Herpes simplex keratitis, Prog. Retin. Eye Res. 2006; 25(4): 355-380.

Holland EJ, Schwartz JS. Classification of herpes simplex virus keratitis, Cornea. 1999; 18(2): 144-154.

Whitley RJ, Baron S. Herpes viruses. In: Medical Microbiology, 4th edition, Galveston (TX), University of Texas Medical Branch at Galveston, 1996. Chapter 68.

Brandt CR. Mixed ocular infections identify strains of herpes simplex virus. J. Virol. Methods. 1991; 35(2): 127-135.

Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM et al. Herpes zoster and human immunodeficiency virus infection. J. Infect. Dis. 1992; 166(5): 1153-1156.

Lundberg P, Welander P, Openshaw H, Nalbandian C, Edwards C et al. A locus on mouse chromosome 6 that determines resistance to herpes simplex virus also influences reactivation while an unlinked locus augments resistance of female mice. J. Virol. 2003; 77(21): 11661-11673.

Jouanguy E, Zhang S-Y, Chapgier A, Sancho-Shimizu V, Puel A et al. Human primary immunodeficiencies of type 1 interferons, Biochimie. 2007; 89(6-7): 878-883.

Lopez C. Genetics of natural resistance to herpes virus infections in mice. Nature. 1975; 258: 152-153.

Divito S, Cherpes TL, Hendricks RL. A triple entente: virus, neurons and CD8+ T cells maintain HSV-1 latency, Immunol. 2006; 36(1-3): 119-126.

Bloom DC. HSV LAT and neuronal survival. Int. Rev. Immunol. 2004; 23(1-2): 187-198.

Perng GS, Jones C. Towards an understanding of the herpes simplex virus type 1 latency reactivation cycle. Interdiscip. Perspect. Infect. Dis. 2010; 2010: 262415.

Kennedy DP, Clement C, Arceneaux RL, Bhattacharjee PS, Huq TS et al. Ocular herpes simplex virus type 1: is the cornea a reservoir for viral latency or a fast pit stop? Cornea. 2011; 30(3): 251-259.

Toma HS, Murina AT, Areaux RG et al. Ocular HSV-1 latency, reactivation and recurrent disease, Semin. Ophthalmol. 2008; 23(4): 249-273.

Richter ER, Dias JK, Gilbert GE, Atherton SS. Distribution of herpes simplex virus type 1 and varicella zoster virus in ganglia of the human head and neck. J. Infect. Dis. 2009; 200(12): 1901-1906.

Fatahzadeh M. Human herpes simplex virus infections: Epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol. 2007; 57(5): 737-763.

Gaynor BD, Margolis TP, Cunningham E. Advances in diagnosis and management of herpetic uveitis, Int. Ophthalmol. Clin. 2000; 40(2): 85-109.

Kaufman HE, Azcuy AM, Varnell ED, Sloop GD. HSV-1 DNA in tears and saliva of normal adults, Invest. Ophthalmol. Vis. Sci. 2005; 46(1): 241-247.

Remeijer R, Maertzdorf J, Doornenbal P, Verjans JM, Osterhaus AD. Herpes simplex virus 1 transmission through corneal transplantation. Lancet. 2001; 357(9254): 442.

Vassileva P. Therapeutic behavior according to the type and stage of ocular herpes, Medinfo. 2013; 13(10): 40-47 [in Bulgarian].

Kaufman HE, Varnell ED, Thompson HW. Latanoprost increases the severity and recurrence of herpetic keratitis in the rabbit. Am. J. Ophthalmol. 1999; 127(5): 531-536.

Cunningham AL, Diefenbach RJ, et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 2006; 194(1): 11-18.

Herpetic Eye Disease Study Group. Predictors of recurrent herpes simplex virus keratitis, Cornea. 2001; 20(2): 123-128.

Kaufman H, Martola EL, Dohlman C. Use of 5-iodo-2′-deoxyuridine (IDU) in treatment of herpes simplex keratitis, Arch. Ophthalmol. 1962; 68: 235-239.

Sibley D, Larkin DFP. Update on Herpes simplex keratitis management. Eye (Lond). 2020 Dec;34(12):2219-2226.

Wilhelmus KR. Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis, Review, Cochrane Database Syst. 2015 Jan; 2015(1): CD002898.

Kaye D, Kaye KM, Aleissa M, Dionne B. Herpes zoster: a potentially dangerous but preventable disease, Healio, News, Infectious Disease, Vaccination. 2019

Cohen EJ, Hochman JS, Troxel AB, Colby KA, Jeng BH; ZEDS Trial Research Group. Zoster Eye Disease Study: Rationale and Design. Cornea 2022;1;41:5:562-571.

Minor M, Payne E. Herpes Zoster Ophthalmicus. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.

Oxman MN, Levin MJ, Johnson GR et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults, N. Engl. J. Med. 2005; 352: 2271-2284.

Poon SHL, Wong WHL, Lo ACY, Yuan H, Chen CF, Jhanji V, Chan YK, Shih KC. A systematic review on advances in diagnostics for herpes simplex keratitis. Surv Ophthalmol. 2021 May-Jun;66(3):514-530.

Weber DJ. Prevention and control of varicella-zoster virus in hospitals. 2020

Vrcek I, Choudhury E, et al. Herpes Zoster Ophthalmicus: A Review for the Internist. Am. J. Med. 2017; 130(1): 21-26.

Kennedy PGE, Cohrs RJ. Varicella-zoster virus human ganglionic latency: a current summary, Review. J. Neurovirol. 2010; 16(6): 411-418.

Goldstein RS, Kinchington PR. Varicella Zoster Virus Neuronal La- tency and Reactivation Modeled in Vitro, Review. Curr. Top. Microbiol. Immunol. 2023; 438: 103-134.



How to Cite

Vassileva P, Kirilova Y. So many scenarios in herpetic eye disease. J.ophthalmol. (Ukraine) [Internet]. 2024 May 1 [cited 2024 May 29];(2):40-8. Available from: